Mycophenolate Mofetil-d4
CAT:
804-HY-B0199S-02
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Mycophenolate Mofetil-d4
- CAS Number: 1132748-21-0
- UNSPSC Description: Mycophenolate Mofetil-d4 is the deuterium labeled Mycophenolate Mofetil. Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH). Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].
- Target Antigen: Apoptosis; Drug Metabolite; Endogenous Metabolite; Isotope-Labeled Compounds
- Type: Isotope-Labeled Compounds
- Related Pathways: Apoptosis;Metabolic Enzyme/Protease;Others
- Field of Research: Cancer
- Purity: 99.47
- Solubility: DMSO : 50 mg/mL (ultrasonic)
- Smiles: CC1=C2C(C(OC2)=O)=C(C(C/C=C(C)/CCC(OC([2H])([2H])C([2H])([2H])N3CCOCC3)=O)=C1OC)O
- Molecular Weight: 437.52
- References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Simmons WD, et al. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17(2):75-92.|[3]Fulton B, et al. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51(2):278-298.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
- Clinical Information: No Development Reported